O

Oragenics
D

OGEN

1.53000
USD
0.10
(6.99%)
مغلق
حجم التداول
45,279
الربح لكل سهم
-11
العائد الربحي
-
P/E
-0
حجم السوق
1,095,240
أصول ذات صلة
A
ALT
-0.14000
(-2.86%)
4.75000 USD
A
ATOS
0.01260
(1.51%)
0.84910 USD
AXON
AXON
18.86
(2.44%)
793.01 USD
C
CLRB
-0.04000
(-0.84%)
4.71000 USD
C
CYCC
-0.01980
(-7.76%)
0.23520 USD
المزيد
الأخبار المقالات

العنوان: Oragenics

القطاع: Healthcare
الصناعة: Biotechnology
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.